China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
August 20, 2026 02:05 PM EDT
R&DChinaIn Focus
Three deaths in China shake trust in the country's speedy clinical trial system
Ryan Cross
Senior Science Correspondent
U.S. House lawmakers say the FDA should not rely on Chinese clinical-trial data without recent inspections, citing opaque…
Death of youngster following experimental gene therapy only made public after journalists investigated
China has tightened regulations on investigator-initiated trials, with consequences not just for Chinese researchers but some…
Scientist says child’s death reveals ‘serious failures in risk assessment, transparency and institutional oversight’.
The death of a six-year-old patient in an investigator-initiated study highlights systemic vulnerabilities in ethics reviews,…
The death of a child during an experimental gene-editing trial renews questions about biotech ethics and ambitions.
